Newly Diagnosed Quality of Life
In newly diagnosed GBM,
QoL was maintained over 12 months in patients treated with Optune Gio™ + TMZ
To measure QoL while using Optune Gio, patients were asked a broad range of questions from the EORTC Quality of Life survey across 5 categories related to daily living and physical-cognitive functioning1,2:
Physical
eg, carrying luggage
Role
eg, work/daily job
Social
eg, family life
Emotional
eg, level of tension
Cognitive
eg, remembering things
Optune Gio did not impact patients’ cognitive function or performance of daily physical activities
Both HCPs and patients reported stable predefined daily functioning scores up to 1 year of Optune Gio use3,4,*,†
- HCP-reported KPS and patient-reported Global Health Status were:
- Maintained from baseline through 12 months of follow-up
- Comparable with the TMZ alone arm
*HCP-reported data collected per KPS assessment at baseline and then repeated monthly. Patient functional status via KPS (at multiple time points) measured patient independence in activities of daily living.
†Patient-reported data collected per EORTC QLQ-C30 at baseline and months 3, 6, 9, and 12. This 30-question survey covered 5 daily functioning domains (Physical, Role, Social, Emotional, and Cognitive).
QoL Over 12 Months3,4
In the pivotal study, patients were treated with the first model of Optune Gio, which was twice as large in size and weight (6 lb) than the currently available device (2.7 lb)
''Optune Gio has been an excellent treatment option for me, and I have been using it for more than two years…it does not impede my movement.''
– Scott, Optune Gio user and Patient Ambassador
Patient image reflects the health status of the patient at the time the photo was taken.
Learn about Optune Gio’s safety profile
EORTC QLQ-C30, European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30; GBM, glioblastoma; HCPs, healthcare professionals; HRQoL, health-related quality of life; KPS, Karnofsky Performance Score; QoL, quality of life; TMZ, temozolomide.
References: 1. Taphoorn MJB, Dirven L, Kanner AA, et al. Influence of treatment with tumor-treating fields and health-related quality of life of patients with newly diagnosed glioblastoma: a secondary analysis of a randomized clinical trial. Supplementary online content. JAMA. 2018;4(4):495-504. Accessed November 14, 2022. https://jamanetwork.com/journals/jamaoncology/fullarticle/2670704 2. EORTC Quality of Life Group. EORTC QLQ-C30, Version 3.0. 1995. European Organisation for Research and Treatment of Cancer, Belgium. 3. Zhu JJ, Demireva P, Kanner AA, et al. Health-related quality of life, cognitive screening, and functional status in a randomized phase III trial (EF-14) of tumor treating fields with temozolomide compared to temozolomide alone in newly diagnosed glioblastoma. J Neurooncol. 2017;135:545-552. 4. Taphoorn MJB, Dirven L, Kanner AA, et al. Influence of treatment with tumor-treating fields on health-related quality of life of patients with newly diagnosed glioblastoma: a secondary analysis of a randomized clinical trial. JAMA Oncol. 2018;4(4):495-504.